| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 97 | 2024 | 2538 | 13.090 |
Why?
|
| Colorectal Neoplasms | 229 | 2024 | 6935 | 11.600 |
Why?
|
| Fluorouracil | 50 | 2024 | 1641 | 3.300 |
Why?
|
| Chemotherapy, Adjuvant | 55 | 2024 | 3514 | 3.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 89 | 2024 | 11742 | 3.080 |
Why?
|
| Rectal Neoplasms | 22 | 2024 | 1157 | 2.840 |
Why?
|
| Neoplasm Staging | 94 | 2024 | 11121 | 2.730 |
Why?
|
| Exercise | 34 | 2024 | 5890 | 2.690 |
Why?
|
| Neoplasm Recurrence, Local | 49 | 2024 | 9280 | 2.500 |
Why?
|
| Microsatellite Instability | 45 | 2024 | 716 | 2.390 |
Why?
|
| Leucovorin | 35 | 2024 | 643 | 2.380 |
Why?
|
| Diet | 36 | 2024 | 8075 | 2.000 |
Why?
|
| Disease-Free Survival | 53 | 2024 | 6814 | 1.900 |
Why?
|
| Organoplatinum Compounds | 24 | 2024 | 407 | 1.750 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 5 | 2024 | 321 | 1.750 |
Why?
|
| Adenocarcinoma | 31 | 2024 | 6346 | 1.550 |
Why?
|
| Life Style | 17 | 2022 | 3917 | 1.500 |
Why?
|
| Camptothecin | 24 | 2022 | 591 | 1.420 |
Why?
|
| Prospective Studies | 134 | 2024 | 54425 | 1.380 |
Why?
|
| Gastrointestinal Neoplasms | 8 | 2023 | 954 | 1.330 |
Why?
|
| CpG Islands | 27 | 2024 | 1230 | 1.280 |
Why?
|
| Liver Neoplasms | 22 | 2024 | 4320 | 1.270 |
Why?
|
| Feeding Behavior | 16 | 2021 | 3188 | 1.220 |
Why?
|
| Body Mass Index | 35 | 2024 | 12953 | 1.220 |
Why?
|
| Peripheral Nervous System Diseases | 6 | 2022 | 710 | 1.210 |
Why?
|
| Aged | 234 | 2024 | 169289 | 1.200 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 24 | 2024 | 899 | 1.180 |
Why?
|
| Leukemia | 4 | 2023 | 1522 | 1.130 |
Why?
|
| Middle Aged | 246 | 2024 | 220895 | 1.130 |
Why?
|
| Proportional Hazards Models | 64 | 2024 | 12463 | 1.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 38 | 2024 | 2057 | 1.100 |
Why?
|
| Motor Activity | 12 | 2015 | 2715 | 1.090 |
Why?
|
| Carcinoma, Hepatocellular | 17 | 2024 | 2298 | 1.080 |
Why?
|
| Humans | 420 | 2024 | 761504 | 1.040 |
Why?
|
| Male | 281 | 2024 | 360804 | 1.010 |
Why?
|
| Female | 296 | 2024 | 392644 | 1.010 |
Why?
|
| Prognosis | 85 | 2024 | 29625 | 1.010 |
Why?
|
| Metformin | 2 | 2024 | 906 | 0.950 |
Why?
|
| Survivors | 12 | 2023 | 2371 | 0.940 |
Why?
|
| Exercise Therapy | 9 | 2020 | 929 | 0.940 |
Why?
|
| Dietary Sucrose | 3 | 2018 | 243 | 0.900 |
Why?
|
| Deoxycytidine | 11 | 2019 | 877 | 0.860 |
Why?
|
| Adiposity | 10 | 2022 | 1878 | 0.860 |
Why?
|
| Medical Oncology | 17 | 2024 | 2321 | 0.860 |
Why?
|
| Follow-Up Studies | 77 | 2024 | 39106 | 0.850 |
Why?
|
| DNA Methylation | 37 | 2024 | 4398 | 0.840 |
Why?
|
| Body Composition | 11 | 2023 | 2426 | 0.830 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 13 | 2022 | 1092 | 0.820 |
Why?
|
| Antineoplastic Agents | 31 | 2024 | 13639 | 0.810 |
Why?
|
| Survival Rate | 41 | 2022 | 12725 | 0.800 |
Why?
|
| Fusobacterium nucleatum | 6 | 2024 | 179 | 0.760 |
Why?
|
| ras Proteins | 21 | 2014 | 1054 | 0.760 |
Why?
|
| Resistance Training | 5 | 2024 | 193 | 0.760 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 3 | 2020 | 208 | 0.750 |
Why?
|
| Hyperinsulinism | 5 | 2023 | 400 | 0.740 |
Why?
|
| Stomach Neoplasms | 11 | 2024 | 1459 | 0.730 |
Why?
|
| Cohort Studies | 66 | 2024 | 41487 | 0.730 |
Why?
|
| Intra-Abdominal Fat | 3 | 2021 | 613 | 0.730 |
Why?
|
| Combined Modality Therapy | 20 | 2024 | 8529 | 0.700 |
Why?
|
| Survival Analysis | 34 | 2021 | 10090 | 0.690 |
Why?
|
| Secondary Prevention | 3 | 2021 | 1475 | 0.690 |
Why?
|
| C-Reactive Protein | 5 | 2024 | 3826 | 0.680 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 4 | 2020 | 416 | 0.680 |
Why?
|
| Adiponectin | 4 | 2024 | 1113 | 0.680 |
Why?
|
| Adult | 160 | 2024 | 221177 | 0.670 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2023 | 277 | 0.670 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2020 | 91 | 0.660 |
Why?
|
| Cyclooxygenase 2 | 9 | 2020 | 597 | 0.610 |
Why?
|
| Phosphatidylinositol 3-Kinases | 21 | 2021 | 2865 | 0.610 |
Why?
|
| Quinazolines | 10 | 2013 | 1371 | 0.600 |
Why?
|
| Long Interspersed Nucleotide Elements | 15 | 2020 | 330 | 0.590 |
Why?
|
| Mutation | 52 | 2024 | 30052 | 0.580 |
Why?
|
| Seafood | 2 | 2018 | 393 | 0.580 |
Why?
|
| Neoplasms | 23 | 2024 | 22170 | 0.580 |
Why?
|
| Inflammation | 5 | 2024 | 10773 | 0.580 |
Why?
|
| Kaplan-Meier Estimate | 30 | 2020 | 6484 | 0.580 |
Why?
|
| Risk Factors | 76 | 2024 | 74206 | 0.570 |
Why?
|
| Aged, 80 and over | 69 | 2024 | 58976 | 0.570 |
Why?
|
| Pancreatic Neoplasms | 15 | 2024 | 5368 | 0.550 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 26 | 2024 | 1745 | 0.550 |
Why?
|
| Sarcopenia | 5 | 2020 | 372 | 0.550 |
Why?
|
| Fatty Acids, Omega-3 | 4 | 2020 | 1390 | 0.540 |
Why?
|
| Clinical Trials, Phase III as Topic | 9 | 2021 | 857 | 0.540 |
Why?
|
| Muscle, Skeletal | 8 | 2023 | 4948 | 0.540 |
Why?
|
| Tumor Microenvironment | 13 | 2022 | 3877 | 0.540 |
Why?
|
| Nutrition Policy | 2 | 2018 | 471 | 0.540 |
Why?
|
| Vitamins | 7 | 2024 | 1635 | 0.530 |
Why?
|
| Obesity | 19 | 2020 | 12947 | 0.530 |
Why?
|
| C-Peptide | 7 | 2024 | 440 | 0.520 |
Why?
|
| Dietary Supplements | 10 | 2024 | 3415 | 0.520 |
Why?
|
| Sweetening Agents | 2 | 2018 | 290 | 0.520 |
Why?
|
| Carcinoma, Signet Ring Cell | 5 | 2018 | 82 | 0.520 |
Why?
|
| Colonic Polyps | 4 | 2022 | 554 | 0.510 |
Why?
|
| Neoplasm Metastasis | 17 | 2019 | 4915 | 0.500 |
Why?
|
| Coffee | 5 | 2022 | 593 | 0.500 |
Why?
|
| Dietary Fats | 3 | 2022 | 1995 | 0.500 |
Why?
|
| Geriatric Assessment | 2 | 2013 | 1410 | 0.490 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2020 | 1934 | 0.480 |
Why?
|
| Esophageal Neoplasms | 7 | 2024 | 1654 | 0.480 |
Why?
|
| Glycemic Index | 3 | 2019 | 396 | 0.470 |
Why?
|
| Fishes | 1 | 2018 | 603 | 0.470 |
Why?
|
| United States | 75 | 2024 | 72334 | 0.470 |
Why?
|
| Population Surveillance | 4 | 2021 | 2598 | 0.470 |
Why?
|
| Data Collection | 3 | 2024 | 3322 | 0.470 |
Why?
|
| Meat Products | 2 | 2019 | 96 | 0.470 |
Why?
|
| Aspirin | 10 | 2024 | 3133 | 0.470 |
Why?
|
| Body Weight | 5 | 2024 | 4618 | 0.460 |
Why?
|
| Anus Neoplasms | 3 | 2024 | 329 | 0.450 |
Why?
|
| Proto-Oncogene Proteins | 19 | 2014 | 4511 | 0.440 |
Why?
|
| Neoadjuvant Therapy | 14 | 2024 | 2827 | 0.440 |
Why?
|
| Energy Metabolism | 5 | 2016 | 2882 | 0.440 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2019 | 646 | 0.440 |
Why?
|
| Physical Exertion | 2 | 2006 | 667 | 0.440 |
Why?
|
| Patient Compliance | 4 | 2024 | 2690 | 0.430 |
Why?
|
| Vitamin D | 11 | 2023 | 3303 | 0.420 |
Why?
|
| Adenoma | 5 | 2022 | 2160 | 0.420 |
Why?
|
| Dairy Products | 3 | 2021 | 490 | 0.420 |
Why?
|
| Neuroendocrine Tumors | 6 | 2013 | 641 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 25 | 2022 | 10209 | 0.410 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2019 | 517 | 0.410 |
Why?
|
| Lymphatic Metastasis | 8 | 2021 | 2915 | 0.390 |
Why?
|
| Interleukin-6 | 6 | 2024 | 3208 | 0.380 |
Why?
|
| Weight Loss | 4 | 2024 | 2684 | 0.380 |
Why?
|
| Calcium, Dietary | 3 | 2019 | 529 | 0.380 |
Why?
|
| Drug Administration Schedule | 13 | 2021 | 4853 | 0.380 |
Why?
|
| Colectomy | 7 | 2020 | 688 | 0.370 |
Why?
|
| Cardiovascular Diseases | 5 | 2022 | 15500 | 0.370 |
Why?
|
| Insulin | 9 | 2019 | 6596 | 0.370 |
Why?
|
| Esophagogastric Junction | 5 | 2024 | 347 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2012 | 748 | 0.360 |
Why?
|
| Antibodies, Monoclonal | 14 | 2014 | 9177 | 0.360 |
Why?
|
| Blood Glucose | 3 | 2017 | 6391 | 0.350 |
Why?
|
| Breast Neoplasms | 6 | 2024 | 21012 | 0.350 |
Why?
|
| Meat | 1 | 2013 | 584 | 0.350 |
Why?
|
| California | 6 | 2020 | 1429 | 0.340 |
Why?
|
| Multivariate Analysis | 18 | 2021 | 12059 | 0.340 |
Why?
|
| Risk Reduction Behavior | 2 | 2019 | 1112 | 0.340 |
Why?
|
| Overweight | 5 | 2016 | 2417 | 0.330 |
Why?
|
| Appendiceal Neoplasms | 2 | 2023 | 155 | 0.330 |
Why?
|
| Recurrence | 7 | 2023 | 8465 | 0.330 |
Why?
|
| Carcinoma | 4 | 2017 | 2330 | 0.330 |
Why?
|
| Somatomedins | 2 | 2008 | 179 | 0.320 |
Why?
|
| Treatment Outcome | 49 | 2024 | 64680 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 7390 | 0.310 |
Why?
|
| Gastroenterology | 1 | 2015 | 577 | 0.310 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2004 | 572 | 0.310 |
Why?
|
| Nuts | 3 | 2019 | 264 | 0.300 |
Why?
|
| Yoga | 2 | 2022 | 281 | 0.300 |
Why?
|
| Anal Canal | 4 | 2023 | 373 | 0.300 |
Why?
|
| Beverages | 4 | 2022 | 821 | 0.300 |
Why?
|
| Dietary Fiber | 4 | 2019 | 759 | 0.300 |
Why?
|
| Health Behavior | 3 | 2015 | 2643 | 0.290 |
Why?
|
| Cisplatin | 6 | 2017 | 1651 | 0.290 |
Why?
|
| Risk Assessment | 25 | 2024 | 23995 | 0.290 |
Why?
|
| Age Factors | 13 | 2024 | 18395 | 0.290 |
Why?
|
| beta Catenin | 8 | 2020 | 1040 | 0.280 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 2319 | 0.270 |
Why?
|
| Weight Gain | 1 | 2016 | 2348 | 0.270 |
Why?
|
| Genes, ras | 4 | 2020 | 654 | 0.270 |
Why?
|
| Receptors, Calcium-Sensing | 2 | 2017 | 318 | 0.260 |
Why?
|
| Confidence Intervals | 4 | 2021 | 2927 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2023 | 20570 | 0.260 |
Why?
|
| Calcifediol | 2 | 2019 | 161 | 0.260 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2007 | 296 | 0.260 |
Why?
|
| Colostomy | 2 | 2018 | 105 | 0.260 |
Why?
|
| Recreation | 1 | 2006 | 125 | 0.260 |
Why?
|
| Radiation Tolerance | 2 | 2018 | 479 | 0.260 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2019 | 557 | 0.260 |
Why?
|
| Energy Intake | 4 | 2018 | 2134 | 0.260 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2021 | 1802 | 0.260 |
Why?
|
| Quality of Life | 13 | 2024 | 13367 | 0.250 |
Why?
|
| Gallbladder Neoplasms | 1 | 2007 | 189 | 0.250 |
Why?
|
| Risk | 9 | 2021 | 9610 | 0.250 |
Why?
|
| Colon | 5 | 2020 | 1792 | 0.250 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2007 | 1784 | 0.240 |
Why?
|
| Comorbidity | 9 | 2022 | 10508 | 0.240 |
Why?
|
| Incidence | 21 | 2024 | 21353 | 0.230 |
Why?
|
| Hypoglycemic Agents | 3 | 2024 | 3085 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2018 | 8547 | 0.230 |
Why?
|
| Dacarbazine | 4 | 2013 | 559 | 0.230 |
Why?
|
| Radiosurgery | 2 | 2024 | 1342 | 0.230 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1376 | 0.230 |
Why?
|
| Pentoxifylline | 1 | 2023 | 53 | 0.220 |
Why?
|
| Stomatitis, Aphthous | 1 | 2023 | 51 | 0.220 |
Why?
|
| Bacteroides fragilis | 1 | 2024 | 252 | 0.210 |
Why?
|
| Behcet Syndrome | 1 | 2023 | 86 | 0.210 |
Why?
|
| Cause of Death | 7 | 2022 | 3683 | 0.210 |
Why?
|
| Diet, Vegetarian | 2 | 2022 | 180 | 0.210 |
Why?
|
| Hypoalbuminemia | 1 | 2023 | 86 | 0.200 |
Why?
|
| Odds Ratio | 13 | 2018 | 9646 | 0.200 |
Why?
|
| Bilirubin | 1 | 2004 | 436 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 4026 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2017 | 2047 | 0.200 |
Why?
|
| Cholangiocarcinoma | 1 | 2007 | 552 | 0.190 |
Why?
|
| Carcinoid Tumor | 3 | 2013 | 224 | 0.190 |
Why?
|
| Bile Duct Neoplasms | 1 | 2007 | 605 | 0.190 |
Why?
|
| Keloid | 1 | 2022 | 54 | 0.190 |
Why?
|
| Cholecalciferol | 2 | 2019 | 553 | 0.190 |
Why?
|
| Retrospective Studies | 21 | 2024 | 80636 | 0.190 |
Why?
|
| Creatine | 1 | 2023 | 427 | 0.190 |
Why?
|
| Digestive System Neoplasms | 1 | 2021 | 82 | 0.190 |
Why?
|
| Hand Strength | 1 | 2024 | 456 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 136 | 0.190 |
Why?
|
| Monosaccharides | 1 | 2021 | 68 | 0.190 |
Why?
|
| Smoking | 6 | 2022 | 9053 | 0.190 |
Why?
|
| Sirolimus | 4 | 2013 | 1533 | 0.190 |
Why?
|
| Alkylating Agents | 1 | 2021 | 133 | 0.180 |
Why?
|
| Young Adult | 19 | 2023 | 59243 | 0.180 |
Why?
|
| Fusobacterium Infections | 1 | 2021 | 53 | 0.180 |
Why?
|
| Molecular Epidemiology | 4 | 2019 | 469 | 0.180 |
Why?
|
| Laxatives | 1 | 2021 | 92 | 0.180 |
Why?
|
| Societies, Medical | 3 | 2018 | 3905 | 0.180 |
Why?
|
| Attitude to Health | 2 | 2019 | 2025 | 0.180 |
Why?
|
| Adenomatous Polyps | 1 | 2021 | 108 | 0.170 |
Why?
|
| Health Personnel | 5 | 2024 | 3335 | 0.170 |
Why?
|
| Nomograms | 1 | 2022 | 230 | 0.170 |
Why?
|
| Flavonoids | 1 | 2023 | 445 | 0.170 |
Why?
|
| Alcohol Drinking | 4 | 2018 | 4028 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 2425 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2021 | 2273 | 0.170 |
Why?
|
| Research Subjects | 1 | 2021 | 249 | 0.170 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2020 | 131 | 0.170 |
Why?
|
| Chemoprevention | 1 | 2022 | 326 | 0.170 |
Why?
|
| Sex Factors | 7 | 2024 | 10552 | 0.170 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1626 | 0.160 |
Why?
|
| Gastrointestinal Motility | 1 | 2021 | 234 | 0.160 |
Why?
|
| Immunohistochemistry | 15 | 2021 | 11076 | 0.160 |
Why?
|
| Autophagy | 2 | 2020 | 1326 | 0.160 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2021 | 245 | 0.160 |
Why?
|
| Endpoint Determination | 2 | 2020 | 590 | 0.160 |
Why?
|
| Caffeine | 3 | 2020 | 700 | 0.160 |
Why?
|
| Granulocytes | 1 | 2021 | 551 | 0.160 |
Why?
|
| Bifidobacteriales Infections | 1 | 2018 | 10 | 0.160 |
Why?
|
| Paraffin Embedding | 1 | 2020 | 302 | 0.160 |
Why?
|
| Tissue Fixation | 1 | 2020 | 241 | 0.160 |
Why?
|
| Genes, DCC | 2 | 2001 | 10 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 3 | 2012 | 883 | 0.160 |
Why?
|
| Formaldehyde | 1 | 2020 | 358 | 0.150 |
Why?
|
| Natural Killer T-Cells | 1 | 2021 | 322 | 0.150 |
Why?
|
| Adipose Tissue | 5 | 2023 | 3312 | 0.150 |
Why?
|
| Phenylurea Compounds | 3 | 2024 | 529 | 0.150 |
Why?
|
| Escherichia coli Infections | 1 | 2022 | 518 | 0.150 |
Why?
|
| Muscular Disorders, Atrophic | 1 | 2018 | 24 | 0.150 |
Why?
|
| Nutrition Surveys | 1 | 2005 | 1733 | 0.150 |
Why?
|
| Bifidobacterium | 1 | 2018 | 97 | 0.150 |
Why?
|
| American Cancer Society | 2 | 2022 | 69 | 0.150 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2021 | 262 | 0.150 |
Why?
|
| Up-Regulation | 6 | 2019 | 4124 | 0.150 |
Why?
|
| Case-Control Studies | 9 | 2024 | 22176 | 0.150 |
Why?
|
| DNA, Neoplasm | 8 | 2023 | 1745 | 0.150 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 69 | 0.140 |
Why?
|
| Lymph Nodes | 3 | 2021 | 3466 | 0.140 |
Why?
|
| Databases, Factual | 8 | 2021 | 7967 | 0.140 |
Why?
|
| Metabolome | 2 | 2024 | 989 | 0.140 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2019 | 269 | 0.140 |
Why?
|
| Receptor, erbB-2 | 2 | 2024 | 2557 | 0.140 |
Why?
|
| Intestinal Neoplasms | 1 | 2019 | 312 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 711 | 0.140 |
Why?
|
| Consensus | 2 | 2024 | 3123 | 0.140 |
Why?
|
| Disease Progression | 5 | 2019 | 13506 | 0.140 |
Why?
|
| Chimerin Proteins | 1 | 2016 | 6 | 0.130 |
Why?
|
| Self Care | 2 | 2019 | 796 | 0.130 |
Why?
|
| Fish Oils | 2 | 2019 | 483 | 0.130 |
Why?
|
| Administration, Oral | 6 | 2016 | 4021 | 0.130 |
Why?
|
| Fructose | 2 | 2022 | 288 | 0.130 |
Why?
|
| Nurses | 6 | 2020 | 2478 | 0.130 |
Why?
|
| Critical Pathways | 1 | 2020 | 474 | 0.130 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2017 | 380 | 0.130 |
Why?
|
| SEER Program | 5 | 2021 | 1450 | 0.130 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3617 | 0.130 |
Why?
|
| DNA Repair Enzymes | 2 | 2008 | 346 | 0.130 |
Why?
|
| Continuity of Patient Care | 1 | 2003 | 1069 | 0.130 |
Why?
|
| Diabetes Complications | 1 | 2003 | 1315 | 0.130 |
Why?
|
| Pyridines | 3 | 2014 | 2875 | 0.130 |
Why?
|
| Epidemiologic Studies | 3 | 2016 | 675 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 750 | 0.130 |
Why?
|
| Medicare | 4 | 2012 | 6770 | 0.130 |
Why?
|
| Nerve Growth Factors | 1 | 1999 | 564 | 0.130 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2019 | 509 | 0.130 |
Why?
|
| Clinical Trials as Topic | 6 | 2024 | 8002 | 0.130 |
Why?
|
| Radiopharmaceuticals | 3 | 2021 | 2651 | 0.130 |
Why?
|
| Phenotype | 13 | 2023 | 16591 | 0.130 |
Why?
|
| Positron-Emission Tomography | 3 | 2021 | 6485 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 3 | 2021 | 2811 | 0.130 |
Why?
|
| Forecasting | 2 | 2022 | 2928 | 0.130 |
Why?
|
| Telomere | 1 | 2022 | 943 | 0.130 |
Why?
|
| Tertiary Prevention | 1 | 2015 | 8 | 0.130 |
Why?
|
| Folic Acid | 2 | 2015 | 1323 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 2020 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 3 | 2020 | 3595 | 0.120 |
Why?
|
| Genes, p16 | 2 | 2017 | 160 | 0.120 |
Why?
|
| Adipokines | 1 | 2017 | 310 | 0.120 |
Why?
|
| Breast Feeding | 1 | 2023 | 1359 | 0.120 |
Why?
|
| Folic Acid Deficiency | 1 | 2015 | 117 | 0.120 |
Why?
|
| Metabolomics | 1 | 2024 | 1659 | 0.120 |
Why?
|
| Tooth Loss | 1 | 2016 | 200 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2021 | 2645 | 0.120 |
Why?
|
| Registries | 4 | 2020 | 8224 | 0.120 |
Why?
|
| Dideoxynucleosides | 1 | 2015 | 135 | 0.120 |
Why?
|
| Melanoma | 2 | 2023 | 5709 | 0.120 |
Why?
|
| Infusions, Intravenous | 3 | 2009 | 2219 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 4 | 2022 | 1702 | 0.120 |
Why?
|
| Lymphocyte Count | 4 | 2020 | 778 | 0.120 |
Why?
|
| Calcium Signaling | 1 | 2019 | 733 | 0.120 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 15266 | 0.110 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2018 | 301 | 0.110 |
Why?
|
| Age of Onset | 1 | 2021 | 3305 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2021 | 980 | 0.110 |
Why?
|
| Loss of Heterozygosity | 4 | 2009 | 662 | 0.110 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 3156 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2016 | 344 | 0.110 |
Why?
|
| Pathology, Molecular | 2 | 2017 | 328 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2021 | 2426 | 0.110 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 11118 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 12148 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2009 | 360 | 0.110 |
Why?
|
| Pilot Projects | 7 | 2023 | 8631 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2024 | 1584 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2024 | 2169 | 0.110 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2015 | 198 | 0.110 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 1479 | 0.110 |
Why?
|
| Adolescent | 14 | 2023 | 88319 | 0.110 |
Why?
|
| Hospitals | 2 | 2004 | 3882 | 0.110 |
Why?
|
| Muscles | 1 | 2018 | 1576 | 0.110 |
Why?
|
| Intestine, Small | 1 | 2019 | 1206 | 0.110 |
Why?
|
| Periodontal Diseases | 1 | 2016 | 451 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 1616 | 0.110 |
Why?
|
| Karnofsky Performance Status | 1 | 2013 | 166 | 0.100 |
Why?
|
| Walking | 1 | 2020 | 1198 | 0.100 |
Why?
|
| Ontario | 1 | 2013 | 398 | 0.100 |
Why?
|
| Vitamin D Deficiency | 2 | 2013 | 1388 | 0.100 |
Why?
|
| Social Class | 1 | 2021 | 2004 | 0.100 |
Why?
|
| Cholesterol | 1 | 2022 | 2904 | 0.100 |
Why?
|
| Television | 1 | 2015 | 408 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 1606 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3245 | 0.100 |
Why?
|
| Diet Records | 3 | 2020 | 427 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2017 | 2803 | 0.100 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 10194 | 0.100 |
Why?
|
| Sarcoma | 1 | 2023 | 1801 | 0.100 |
Why?
|
| Adolescent Behavior | 1 | 2021 | 1190 | 0.100 |
Why?
|
| Codon | 1 | 2014 | 601 | 0.100 |
Why?
|
| Income | 1 | 2021 | 1877 | 0.100 |
Why?
|
| Germ-Line Mutation | 4 | 2018 | 1858 | 0.100 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 741 | 0.100 |
Why?
|
| Biomedical Research | 3 | 2019 | 3429 | 0.100 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 9420 | 0.100 |
Why?
|
| Diet, Mediterranean | 2 | 2019 | 740 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 1613 | 0.100 |
Why?
|
| Brain Neoplasms | 3 | 2021 | 9031 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2021 | 2093 | 0.100 |
Why?
|
| Vitamin B 6 | 1 | 2013 | 234 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2023 | 5671 | 0.100 |
Why?
|
| Monocytes | 1 | 2021 | 2570 | 0.100 |
Why?
|
| Time Factors | 12 | 2021 | 39967 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2024 | 1727 | 0.100 |
Why?
|
| Neuroblastoma | 2 | 2001 | 1250 | 0.100 |
Why?
|
| Tegafur | 2 | 2013 | 39 | 0.100 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2009 | 83 | 0.090 |
Why?
|
| Logistic Models | 7 | 2024 | 13255 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 1403 | 0.090 |
Why?
|
| DNA Mismatch Repair | 3 | 2023 | 428 | 0.090 |
Why?
|
| Animals | 15 | 2024 | 168459 | 0.090 |
Why?
|
| Epigenomics | 2 | 2017 | 943 | 0.090 |
Why?
|
| Cell Lineage | 1 | 2020 | 2555 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2009 | 319 | 0.090 |
Why?
|
| Interdisciplinary Communication | 2 | 2015 | 931 | 0.090 |
Why?
|
| Physical Fitness | 2 | 2013 | 743 | 0.090 |
Why?
|
| Vitamin B Complex | 1 | 2013 | 299 | 0.090 |
Why?
|
| Dietary Carbohydrates | 2 | 2012 | 891 | 0.090 |
Why?
|
| Lymphocytes | 3 | 2020 | 2612 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 282 | 0.090 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2008 | 269 | 0.090 |
Why?
|
| Diet Therapy | 1 | 2011 | 151 | 0.090 |
Why?
|
| Epidemiology | 1 | 2013 | 279 | 0.090 |
Why?
|
| Gastrectomy | 2 | 2007 | 672 | 0.090 |
Why?
|
| Enkephalins | 1 | 1990 | 139 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2016 | 3816 | 0.090 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 302 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 4544 | 0.090 |
Why?
|
| MutS Homolog 2 Protein | 3 | 2017 | 197 | 0.090 |
Why?
|
| Hydroxychloroquine | 1 | 2014 | 426 | 0.090 |
Why?
|
| Intestinal Perforation | 1 | 2012 | 249 | 0.090 |
Why?
|
| Genes, bcl-1 | 1 | 2009 | 11 | 0.080 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2009 | 68 | 0.080 |
Why?
|
| HLA-DR Antigens | 2 | 2021 | 602 | 0.080 |
Why?
|
| Calcium | 2 | 2019 | 5722 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 1935 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 1177 | 0.080 |
Why?
|
| Rectum | 3 | 2019 | 892 | 0.080 |
Why?
|
| Insulin Resistance | 2 | 2021 | 3963 | 0.080 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 283 | 0.080 |
Why?
|
| Nausea | 2 | 2016 | 679 | 0.080 |
Why?
|
| Waist Circumference | 2 | 2024 | 935 | 0.080 |
Why?
|
| Telephone | 1 | 2011 | 627 | 0.080 |
Why?
|
| Tea | 2 | 2023 | 288 | 0.080 |
Why?
|
| Health Occupations | 2 | 2021 | 222 | 0.070 |
Why?
|
| Safety | 1 | 2012 | 1150 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2009 | 617 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 615 | 0.070 |
Why?
|
| Pandemics | 3 | 2022 | 8654 | 0.070 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2009 | 185 | 0.070 |
Why?
|
| Albumins | 2 | 2023 | 575 | 0.070 |
Why?
|
| Subcutaneous Fat | 2 | 2021 | 393 | 0.070 |
Why?
|
| Quinolines | 1 | 2013 | 764 | 0.070 |
Why?
|
| Standard of Care | 1 | 2011 | 551 | 0.070 |
Why?
|
| Research Design | 3 | 2020 | 6180 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2021 | 2010 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 13380 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2024 | 10766 | 0.070 |
Why?
|
| Mass Screening | 1 | 2003 | 5428 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2022 | 5079 | 0.070 |
Why?
|
| Receptors, Calcitriol | 1 | 2009 | 360 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2017 | 3442 | 0.070 |
Why?
|
| Decision Making | 3 | 2020 | 3929 | 0.070 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2010 | 598 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2020 | 3600 | 0.070 |
Why?
|
| Testis | 1 | 1990 | 794 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 3201 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 1250 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2021 | 2469 | 0.070 |
Why?
|
| Oxonic Acid | 1 | 2006 | 31 | 0.070 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 210 | 0.070 |
Why?
|
| Genomics | 2 | 2023 | 5821 | 0.070 |
Why?
|
| Genes | 1 | 1990 | 1823 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 1886 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 1705 | 0.070 |
Why?
|
| Preoperative Care | 3 | 2023 | 2242 | 0.070 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 1897 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 619 | 0.070 |
Why?
|
| Prevalence | 4 | 2023 | 15732 | 0.070 |
Why?
|
| Tocopherols | 1 | 2005 | 44 | 0.070 |
Why?
|
| Protein Precursors | 1 | 1990 | 1132 | 0.070 |
Why?
|
| Endostatins | 1 | 2006 | 168 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2007 | 7856 | 0.060 |
Why?
|
| Surgery Department, Hospital | 1 | 2007 | 176 | 0.060 |
Why?
|
| DNA Mutational Analysis | 5 | 2017 | 4111 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 592 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4580 | 0.060 |
Why?
|
| Intention to Treat Analysis | 2 | 2018 | 413 | 0.060 |
Why?
|
| Neutrophils | 1 | 2017 | 3767 | 0.060 |
Why?
|
| Watchful Waiting | 2 | 2019 | 491 | 0.060 |
Why?
|
| Diet Surveys | 2 | 2019 | 1162 | 0.060 |
Why?
|
| Observation | 1 | 2006 | 310 | 0.060 |
Why?
|
| Salvage Therapy | 2 | 2009 | 1264 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2017 | 17904 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2011 | 5789 | 0.060 |
Why?
|
| Length of Stay | 2 | 2020 | 6425 | 0.060 |
Why?
|
| Biopsy | 3 | 2023 | 6766 | 0.060 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 186 | 0.060 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2004 | 70 | 0.060 |
Why?
|
| Levamisole | 1 | 2003 | 35 | 0.060 |
Why?
|
| Nutritional Status | 1 | 2012 | 1615 | 0.060 |
Why?
|
| Piperidines | 1 | 2012 | 1656 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 3416 | 0.050 |
Why?
|
| Estradiol | 1 | 2010 | 1937 | 0.050 |
Why?
|
| Appetite | 1 | 2005 | 247 | 0.050 |
Why?
|
| Nucleocapsid | 1 | 2023 | 63 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 3 | 2009 | 247 | 0.050 |
Why?
|
| Prodrugs | 1 | 2005 | 261 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 20098 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2018 | 6567 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2023 | 1732 | 0.050 |
Why?
|
| Pyrroles | 1 | 2009 | 1125 | 0.050 |
Why?
|
| Health Promotion | 1 | 2015 | 2214 | 0.050 |
Why?
|
| Anxiety | 1 | 2017 | 4573 | 0.050 |
Why?
|
| Carotenoids | 1 | 2005 | 621 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2022 | 64 | 0.050 |
Why?
|
| Nutrition Assessment | 1 | 2005 | 728 | 0.050 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2006 | 339 | 0.050 |
Why?
|
| Hypertension | 1 | 2022 | 8540 | 0.050 |
Why?
|
| Genotype | 4 | 2022 | 12990 | 0.050 |
Why?
|
| Poultry | 1 | 2022 | 80 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2014 | 2455 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2017 | 11528 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2015 | 3537 | 0.050 |
Why?
|
| Furosemide | 1 | 2022 | 170 | 0.050 |
Why?
|
| Niacinamide | 1 | 2024 | 413 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 4 | 2013 | 6075 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2008 | 1608 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2013 | 297 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 5821 | 0.050 |
Why?
|
| Inpatients | 1 | 2013 | 2548 | 0.050 |
Why?
|
| ROC Curve | 2 | 2020 | 3579 | 0.050 |
Why?
|
| Escherichia coli | 2 | 2024 | 4217 | 0.050 |
Why?
|
| Indoles | 1 | 2009 | 1833 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 551 | 0.050 |
Why?
|
| Intention | 1 | 2024 | 347 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2007 | 1509 | 0.050 |
Why?
|
| Republic of Korea | 2 | 2013 | 590 | 0.050 |
Why?
|
| Marital Status | 1 | 2022 | 426 | 0.050 |
Why?
|
| Muscular Atrophy | 1 | 2023 | 334 | 0.040 |
Why?
|
| Hematoxylin | 1 | 2020 | 60 | 0.040 |
Why?
|
| Medical Record Linkage | 2 | 2012 | 285 | 0.040 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2020 | 69 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2020 | 1893 | 0.040 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2023 | 421 | 0.040 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 1386 | 0.040 |
Why?
|
| Withholding Treatment | 2 | 2017 | 617 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2023 | 385 | 0.040 |
Why?
|
| North America | 1 | 2004 | 1276 | 0.040 |
Why?
|
| Poverty Areas | 1 | 2021 | 263 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2006 | 1208 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2004 | 706 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 621 | 0.040 |
Why?
|
| Health Surveys | 3 | 2017 | 4061 | 0.040 |
Why?
|
| Liver | 2 | 2019 | 7529 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 641 | 0.040 |
Why?
|
| Patient Dropouts | 2 | 2013 | 412 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2009 | 2416 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 1999 | 13446 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 983 | 0.040 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 26125 | 0.040 |
Why?
|
| Public Health | 1 | 2013 | 2669 | 0.040 |
Why?
|
| Postural Balance | 1 | 2024 | 622 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2017 | 2917 | 0.040 |
Why?
|
| Cancer Care Facilities | 2 | 2014 | 422 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2024 | 1089 | 0.040 |
Why?
|
| Macrophage Activation | 2 | 2020 | 553 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2009 | 1978 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2022 | 694 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2019 | 12341 | 0.040 |
Why?
|
| Edema | 1 | 2023 | 766 | 0.040 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 374 | 0.040 |
Why?
|
| Canada | 2 | 2017 | 2122 | 0.040 |
Why?
|
| Base Sequence | 4 | 2012 | 12441 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 1999 | 17635 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2022 | 552 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2009 | 2009 | 0.040 |
Why?
|
| Trans Fatty Acids | 1 | 2019 | 155 | 0.040 |
Why?
|
| Rectus Abdominis | 1 | 2019 | 103 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2020 | 5247 | 0.040 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 224 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2011 | 5305 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 1486 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3810 | 0.040 |
Why?
|
| Smoking Cessation | 1 | 2010 | 2056 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 794 | 0.040 |
Why?
|
| Cytokines | 1 | 2013 | 7396 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 1626 | 0.040 |
Why?
|
| Fatigue | 1 | 2005 | 1552 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2022 | 701 | 0.040 |
Why?
|
| Epirubicin | 1 | 2017 | 81 | 0.040 |
Why?
|
| Depression | 1 | 2017 | 8124 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2023 | 611 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2003 | 746 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2005 | 1808 | 0.040 |
Why?
|
| Feces | 1 | 2024 | 1497 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 325 | 0.040 |
Why?
|
| Automation | 1 | 2020 | 586 | 0.040 |
Why?
|
| Saliva | 1 | 2022 | 828 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 867 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2023 | 1738 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 1992 | 7594 | 0.040 |
Why?
|
| Pyridones | 1 | 2023 | 809 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 1188 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2024 | 2224 | 0.040 |
Why?
|
| Pain | 2 | 2022 | 5073 | 0.030 |
Why?
|
| COS Cells | 1 | 1999 | 1130 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2024 | 1336 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 4243 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2022 | 1241 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 3492 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2003 | 2898 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2017 | 181 | 0.030 |
Why?
|
| Cadherins | 1 | 2001 | 903 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2017 | 125 | 0.030 |
Why?
|
| Motivation | 2 | 2019 | 2006 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 1039 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2020 | 1085 | 0.030 |
Why?
|
| Anorexia | 1 | 2016 | 154 | 0.030 |
Why?
|
| Nuclear Proteins | 4 | 2017 | 5796 | 0.030 |
Why?
|
| Microsatellite Repeats | 2 | 2009 | 784 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 1115 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2017 | 315 | 0.030 |
Why?
|
| Pancreas | 1 | 2022 | 1691 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1997 | 1545 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2001 | 1342 | 0.030 |
Why?
|
| Europe | 1 | 2002 | 3422 | 0.030 |
Why?
|
| Patient Preference | 1 | 2022 | 924 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 1661 | 0.030 |
Why?
|
| Penetrance | 1 | 2017 | 383 | 0.030 |
Why?
|
| Morbidity | 1 | 2020 | 1750 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 728 | 0.030 |
Why?
|
| Nutritive Value | 1 | 2018 | 350 | 0.030 |
Why?
|
| Chickens | 1 | 1997 | 859 | 0.030 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 1336 | 0.030 |
Why?
|
| DNA | 2 | 2024 | 7212 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 629 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2001 | 1600 | 0.030 |
Why?
|
| Breast | 1 | 2023 | 1967 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2330 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 2748 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 5840 | 0.030 |
Why?
|
| Food, Fortified | 1 | 2015 | 190 | 0.030 |
Why?
|
| Program Development | 1 | 2020 | 1297 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2001 | 3087 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2022 | 1819 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1787 | 0.030 |
Why?
|
| Demography | 1 | 2019 | 1648 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 550 | 0.030 |
Why?
|
| Gene Expression | 2 | 2014 | 7581 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2021 | 2645 | 0.030 |
Why?
|
| Leisure Activities | 1 | 2015 | 308 | 0.030 |
Why?
|
| Leukocytes | 1 | 2022 | 2026 | 0.030 |
Why?
|
| Fruit | 1 | 2019 | 1160 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2008 | 698 | 0.030 |
Why?
|
| Vegetables | 1 | 2019 | 1195 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 2078 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2020 | 1242 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 601 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1997 | 1991 | 0.030 |
Why?
|
| Infant | 3 | 2023 | 36192 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2019 | 908 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 3712 | 0.030 |
Why?
|
| Mice | 6 | 2024 | 81525 | 0.030 |
Why?
|
| Palliative Care | 2 | 2014 | 3598 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2008 | 3482 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2016 | 659 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 123 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 803 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 764 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 2024 | 0.030 |
Why?
|
| Pancreatectomy | 1 | 2017 | 811 | 0.030 |
Why?
|
| Macrophages | 2 | 2021 | 5769 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2008 | 2898 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 3461 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 2200 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2023 | 12795 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 2254 | 0.030 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 5486 | 0.030 |
Why?
|
| Signal Transduction | 5 | 2014 | 23445 | 0.020 |
Why?
|
| Lymph Node Excision | 2 | 2009 | 1271 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2020 | 2495 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 6310 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2019 | 2696 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2020 | 1394 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 2850 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2016 | 1870 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 4352 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2012 | 6343 | 0.020 |
Why?
|
| Minnesota | 1 | 2011 | 338 | 0.020 |
Why?
|
| Hydroxyestrones | 1 | 2010 | 17 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2001 | 2856 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 2016 | 0.020 |
Why?
|
| Eating | 1 | 2018 | 1539 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 379 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 14031 | 0.020 |
Why?
|
| Patient Participation | 1 | 2020 | 1444 | 0.020 |
Why?
|
| RNA Probes | 1 | 1990 | 111 | 0.020 |
Why?
|
| Internet | 1 | 2023 | 3092 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2022 | 2576 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1999 | 4615 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 664 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 1998 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 625 | 0.020 |
Why?
|
| Genomic Library | 1 | 1990 | 189 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 2020 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 400 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 5492 | 0.020 |
Why?
|
| Causality | 1 | 2016 | 1242 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2017 | 1804 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2011 | 376 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1990 | 851 | 0.020 |
Why?
|
| Skin | 1 | 2023 | 4484 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2005 | 4481 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 9606 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 768 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 1992 | 358 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 1999 | 1456 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1745 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9757 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 558 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1997 | 5035 | 0.020 |
Why?
|
| Epidemiologic Research Design | 1 | 2013 | 368 | 0.020 |
Why?
|
| DNA Probes | 1 | 1990 | 541 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2010 | 8320 | 0.020 |
Why?
|
| Gene Deletion | 1 | 1997 | 2665 | 0.020 |
Why?
|
| Spermatogenesis | 1 | 1990 | 259 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2013 | 793 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1058 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2003 | 3530 | 0.020 |
Why?
|
| DNA Repair | 1 | 2018 | 2045 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2012 | 774 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2017 | 6228 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2008 | 129 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1992 | 1248 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 2606 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2008 | 127 | 0.020 |
Why?
|
| Calcium Channels, T-Type | 1 | 2008 | 28 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 2691 | 0.020 |
Why?
|
| Physician's Role | 1 | 2015 | 917 | 0.020 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2008 | 57 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 7827 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 1520 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2013 | 2281 | 0.020 |
Why?
|
| Linear Models | 1 | 2017 | 5871 | 0.020 |
Why?
|
| Introns | 1 | 1990 | 981 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 1666 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2021 | 26198 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2003 | 4652 | 0.020 |
Why?
|
| Epigenesis, Genetic | 2 | 2012 | 3802 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2009 | 454 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 1171 | 0.020 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2008 | 224 | 0.020 |
Why?
|
| DNA Primers | 1 | 2011 | 2819 | 0.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 178 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2011 | 718 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 3688 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1612 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2018 | 2521 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 2880 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 1380 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 1567 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 709 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2013 | 1468 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 2 | 2010 | 4414 | 0.020 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2006 | 46 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2020 | 3270 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2018 | 2176 | 0.020 |
Why?
|
| Patient Selection | 1 | 2018 | 4244 | 0.020 |
Why?
|
| Species Specificity | 1 | 1990 | 2414 | 0.020 |
Why?
|
| Alleles | 1 | 1997 | 6863 | 0.020 |
Why?
|
| Child | 3 | 2021 | 80153 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 1505 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 1596 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1990 | 1967 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 668 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 3734 | 0.020 |
Why?
|
| Self Administration | 1 | 2006 | 390 | 0.020 |
Why?
|
| RNA Stability | 1 | 2007 | 329 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 3615 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 681 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2021 | 42230 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2012 | 2919 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2020 | 18965 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 2006 | 6534 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12974 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2008 | 1834 | 0.010 |
Why?
|
| Mortality | 1 | 2015 | 2901 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 5440 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 2385 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 14605 | 0.010 |
Why?
|
| Remission Induction | 1 | 2008 | 2396 | 0.010 |
Why?
|
| Telemedicine | 1 | 2020 | 3051 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 3429 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3778 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4575 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 1136 | 0.010 |
Why?
|
| Desmogleins | 1 | 2001 | 4 | 0.010 |
Why?
|
| Radiography | 1 | 2012 | 6965 | 0.010 |
Why?
|
| alpha Catenin | 1 | 2001 | 37 | 0.010 |
Why?
|
| Desmoplakins | 1 | 2001 | 61 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2016 | 9318 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2007 | 2601 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 4740 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9326 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 2001 | 239 | 0.010 |
Why?
|
| Heterozygote | 1 | 2007 | 2787 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2006 | 2048 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2008 | 2057 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 6132 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 15936 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2010 | 3113 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 15842 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2015 | 4686 | 0.010 |
Why?
|
| Postmenopause | 1 | 2006 | 2513 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2001 | 1494 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2014 | 4811 | 0.010 |
Why?
|
| Stem Cells | 1 | 2009 | 3522 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 9486 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 11903 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 16981 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 23742 | 0.010 |
Why?
|
| Massachusetts | 1 | 2007 | 8830 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 3448 | 0.010 |
Why?
|
| Hospitalization | 1 | 2014 | 10723 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 9469 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 5774 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2006 | 4936 | 0.010 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1992 | 262 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 2822 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2007 | 4792 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15631 | 0.010 |
Why?
|
| Feedback | 1 | 1992 | 791 | 0.000 |
Why?
|
| Protein Biosynthesis | 1 | 1992 | 2113 | 0.000 |
Why?
|
| Cell Division | 1 | 1992 | 4465 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1992 | 6216 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 36426 | 0.000 |
Why?
|